摘要
目的探讨齐拉西酮联合丙戊酸钠治疗精神分裂症的临床疗效。方法通过对整群选取2011年2月—2015年4月在该院进行治疗的82例精神分裂症患者随机分组,其中对照组患者应用齐拉西酮治疗,实验组患者实施齐拉西酮联合丙戊酸钠治疗。观察比较两组患者治疗效果、PASS评分和不良反应发生率差异。结果实验组患者总有效率明显高于对照组、PASS评分显著改善,差异具有统计学意义(P<0.05),两组患者不良反应发生率差异无统计学意义(P>0.05)。结论齐拉西酮联合丙戊酸钠治疗精神分裂症可明显提高治疗效果,降低PASS评分,无严重不良反应,其具有安全有效等特点,临床值得推广应用。
Objective To evaluate the clinical efficacy of ziprasidone in the treatment of schizophrenia combined with valproate.Methods By February 2011 to April 2015 in our hospital for treatment of 82 cases of patients with schizophrenia randomized control group in which patients ziprasidone treatment, the experimental group was treated ziprasidone joint valproate sodium treatment.To compare the two groups of patient outcomes, PASS scores and differences in the incidence of adverse reactions. Results The experimental group was significantly higher total efficiency, PASS scores improved significantly, the difference was statistically sig-nificant(P<0.05), the incidence of adverse reactions was not statistically significant(P>0.05). Conclusion Ziprasidone joint valproate therapy can significantly improve the treatment of schizophrenia, reduce PASS scores, no serious adverse reactions, it is safe and effective features, clinical worth promoting.
出处
《中外医疗》
2015年第28期145-146,共2页
China & Foreign Medical Treatment
